Literature DB >> 22327296

The same pocket in menin binds both MLL and JUND but has opposite effects on transcription.

Jing Huang1, Buddha Gurung, Bingbing Wan, Smita Matkar, Natalia A Veniaminova, Ke Wan, Juanita L Merchant, Xianxin Hua, Ming Lei.   

Abstract

Menin is a tumour suppressor protein whose loss or inactivation causes multiple endocrine neoplasia 1 (MEN1), a hereditary autosomal dominant tumour syndrome that is characterized by tumorigenesis in multiple endocrine organs. Menin interacts with many proteins and is involved in a variety of cellular processes. Menin binds the JUN family transcription factor JUND and inhibits its transcriptional activity. Several MEN1 missense mutations disrupt the menin-JUND interaction, suggesting a correlation between the tumour-suppressor function of menin and its suppression of JUND-activated transcription. Menin also interacts with mixed lineage leukaemia protein 1 (MLL1), a histone H3 lysine 4 methyltransferase, and functions as an oncogenic cofactor to upregulate gene transcription and promote MLL1-fusion-protein-induced leukaemogenesis. A recent report on the tethering of MLL1 to chromatin binding factor lens epithelium-derived growth factor (LEDGF) by menin indicates that menin is a molecular adaptor coordinating the functions of multiple proteins. Despite its importance, how menin interacts with many distinct partners and regulates their functions remains poorly understood. Here we present the crystal structures of human menin in its free form and in complexes with MLL1 or with JUND, or with an MLL1-LEDGF heterodimer. These structures show that menin contains a deep pocket that binds short peptides of MLL1 or JUND in the same manner, but that it can have opposite effects on transcription. The menin-JUND interaction blocks JUN N-terminal kinase (JNK)-mediated JUND phosphorylation and suppresses JUND-induced transcription. In contrast, menin promotes gene transcription by binding the transcription activator MLL1 through the peptide pocket while still interacting with the chromatin-anchoring protein LEDGF at a distinct surface formed by both menin and MLL1.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22327296      PMCID: PMC3983792          DOI: 10.1038/nature10806

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  27 in total

Review 1.  In search of tumor suppressing functions of menin.

Authors:  Yuqing Yang; Xianxin Hua
Journal:  Mol Cell Endocrinol       Date:  2007-01-11       Impact factor: 4.102

2.  Menin critically links MLL proteins with LEDGF on cancer-associated target genes.

Authors:  Akihiko Yokoyama; Michael L Cleary
Journal:  Cancer Cell       Date:  2008-07-08       Impact factor: 31.743

3.  Differential targeting of MAP kinases to the ETS-domain transcription factor Elk-1.

Authors:  S H Yang; A J Whitmarsh; R J Davis; A D Sharrocks
Journal:  EMBO J       Date:  1998-03-16       Impact factor: 11.598

Review 4.  Tetratrico peptide repeat interactions: to TPR or not to TPR?

Authors:  J R Lamb; S Tugendreich; P Hieter
Journal:  Trends Biochem Sci       Date:  1995-07       Impact factor: 13.807

5.  Multiple endocrine neoplasia type 1 interacts with forkhead transcription factor CHES1 in DNA damage response.

Authors:  Valeria Busygina; Molly C Kottemann; Kenneth L Scott; Sharon E Plon; Allen E Bale
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

Review 6.  Modulation of the composition of AP-1 complex and its impact on transcriptional activity.

Authors:  B Kaminska; B Pyrzynska; I Ciechomska; M Wisniewska
Journal:  Acta Neurobiol Exp (Wars)       Date:  2000       Impact factor: 1.579

7.  The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis.

Authors:  Akihiko Yokoyama; Tim C P Somervaille; Kevin S Smith; Orit Rozenblatt-Rosen; Matthew Meyerson; Michael L Cleary
Journal:  Cell       Date:  2005-10-21       Impact factor: 41.582

8.  Menin promotes the Wnt signaling pathway in pancreatic endocrine cells.

Authors:  Gao Chen; Jingbo A; Min Wang; Steven Farley; Lung-Yi Lee; Lung-Ching Lee; Mark P Sawicki
Journal:  Mol Cancer Res       Date:  2008-12       Impact factor: 5.852

9.  Menin uncouples Elk-1, JunD and c-Jun phosphorylation from MAP kinase activation.

Authors:  Adriana Gallo; Concetta Cuozzo; Ilaria Esposito; Marcello Maggiolini; Daniela Bonofiglio; Adele Vivacqua; Maria Garramone; Carsten Weiss; Dirk Bohmann; Anna Maria Musti
Journal:  Oncogene       Date:  2002-09-19       Impact factor: 9.867

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  123 in total

1.  miR-24 Inhibition Increases Menin Expression and Decreases Cholangiocarcinoma Proliferation.

Authors:  Laurent Ehrlich; Chad Hall; Julie Venter; David Dostal; Francesca Bernuzzi; Pietro Invernizzi; Fanyin Meng; Jerome P Trzeciakowski; Tianhao Zhou; Holly Standeford; Gianfranco Alpini; Terry C Lairmore; Shannon Glaser
Journal:  Am J Pathol       Date:  2017-01-11       Impact factor: 4.307

Review 2.  Small molecule epigenetic inhibitors targeted to histone lysine methyltransferases and demethylases.

Authors:  Zhanxin Wang; Dinshaw J Patel
Journal:  Q Rev Biophys       Date:  2013-09-02       Impact factor: 5.318

3.  Menin immunoreactivity in secretory granules of human pancreatic islet cells.

Authors:  Larisa V Debelenko; Sunita Agarwal; Qiang Du; Wusheng Yan; Heidi S Erickson; Mones Abu-Asab; Mark A Raffeld; Steven K Libutti; Stephen J Marx; Michael R Emmert-Buck
Journal:  Appl Immunohistochem Mol Morphol       Date:  2014 Nov-Dec

Review 4.  Evolution of Our Understanding of the Hyperparathyroid Syndromes: A Historical Perspective.

Authors:  Stephen J Marx; David Goltzman
Journal:  J Bone Miner Res       Date:  2018-12-10       Impact factor: 6.741

Review 5.  Multiple endocrine neoplasia type 1.

Authors:  Sunita K Agarwal
Journal:  Front Horm Res       Date:  2013-03-19       Impact factor: 2.606

Review 6.  Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia.

Authors:  Bin E Li; Patricia Ernst
Journal:  Exp Hematol       Date:  2014-09-28       Impact factor: 3.084

7.  Menin is required for optimal processing of the microRNA let-7a.

Authors:  Buddha Gurung; Abdul Bari Muhammad; Xianxin Hua
Journal:  J Biol Chem       Date:  2014-02-21       Impact factor: 5.157

8.  Neuron-Specific Menin Deletion Leads to Synaptic Dysfunction and Cognitive Impairment by Modulating p35 Expression.

Authors:  Kai Zhuang; Changquan Huang; Lige Leng; Honghua Zheng; Yuehong Gao; Guimiao Chen; Zhilin Ji; Hao Sun; Yu Hu; Di Wu; Meng Shi; Huifang Li; Yingjun Zhao; Yunwu Zhang; Maoqiang Xue; Guojun Bu; Timothy Y Huang; Huaxi Xu; Jie Zhang
Journal:  Cell Rep       Date:  2018-07-17       Impact factor: 9.423

9.  PTCH 1 staining of pancreatic neuroendocrine tumor (PNET) samples from patients with and without multiple endocrine neoplasia (MEN-1) syndrome reveals a potential therapeutic target.

Authors:  Buddha Gurung; Xianxin Hua; Melissa Runske; Bonita Bennett; Virginia LiVolsi; Robert Roses; Douglas A Fraker; David C Metz
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

Review 10.  Therapeutic implications of menin inhibition in acute leukemias.

Authors:  Ghayas C Issa; Farhad Ravandi; Courtney D DiNardo; Elias Jabbour; Hagop M Kantarjian; Michael Andreeff
Journal:  Leukemia       Date:  2021-06-15       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.